Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Anova Enterprises has launched the AnovaOS SaaS platform, a new AI-based patient matching solution for clinical trials.

MajesTEC-3 gives J&J a way to keep Darzalex relevant beyond its 2029 patent cliff. Credit: aipicte via Shutterstock. At the American Society of Hematology (ASH) Annual Meeting 2025, held in Orlando, ...

Capricor’s stock shot up by 371% after it announced the HOPE-3 data. Image credit: Lightspring / Shutterstock.com. Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of ...

The safety profile of atogepant over the 24-week period aligned with earlier studies of its use in migraine prevention, with no new safety signals observed. Credit: Komsan Loonprom / Shutterstock.com.

The FDA has debuted a framework that is designed to help companies move away from the use of non-human primate preclinical toxicology testing. Image credit: Deniz_Guler via Shutterstock.com. The US ...

Immunome’s acquired gamma secretase inhibitor, varegacestat, has demonstrated its efficacy and tolerability in a Phase III study, meaning the company will now file for the drug’s approval with the FDA ...

Spinogenix’s first-in-class ALS treatment, SPG302 has been shown to slow disease progression in 82% of patients during a Phase IIa study. Image credit: David Herraez Calzada via Shutterstock.com.

Produodopa is an alternative to AbbVie’s own Duodopa. Credit: Michael Vi via Shutterstock. On 9 January 2024, AbbVie announced the launch of Produodopa ...

Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...